Tezepelumab is effective in older patients with type 2 severe asthma, and baseline serum cytokine levels may be useful in predicting the efficacy of tezepelumab

Key Points

• To evaluate the effectiveness of tezepelumab in older patients with type 2 severe asthma and assess the role of serum cytokine levels in predicting treatment efficacy.
• Analyzed the efficacy of tezepelumab in patients with type 2 and non-type 2 asthma
• Measured baseline serum cytokine levels, specifically ST2 and IL-33R
• Compared treatment outcomes between older patients with type 2 asthma and other classifications
• Tezepelumab showed greater effectiveness in older patients with type 2 asthma
• Baseline serum levels of ST2 and IL-33R may predict the efficacy of tezepelumab
• Need for larger studies to confirm findings